Gubra A/S (GUBRA) Partner Shows Phase 1 ABBV-295 Tolerability, PK

Gubra said partner AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, showing favorable tolerability and pharmacokinetics supporting dosing beyond weekly in a 12/13-week MAD study.Material DetailsContext by AI AnalystThis is early-stage validation of a partnered obesi…